High‐dose chemotherapy showed no clear difference in overall survival at 5‐year compared with chemotherapy without bone marrow transplant or stem cell rescue (high certainty).
High‐dose chemotherapy showed no clear difference in event‐free survival at 5‐year compared with chemotherapy without bone marrow transplant or stem cell rescue (high certainty).
High‐dose chemotherapy leads to higher treatment‐related mortality compared with chemotherapy without bone marrow transplant or stem cell rescue (high certainty).
High‐dose chemotherapy showed no clear difference in second cancers at 4 ‐ 9‐year median compared with chemotherapy without bone marrow transplant or stem cell rescue (high certainty).
Hypofractionated radiation therapy showed no clear difference in local recurrence‐free survival (LR‐FS) at 10 years compared with conventionally fractionated radiation therapy (high certainty).
Hypofractionated radiation therapy showed no clear difference in cosmesis compared with conventionally fractionated radiation therapy (high certainty).
Hypofractionated radiation therapy showed no clear difference in mortality at 10 years compared with conventionally fractionated radiation therapy (high certainty).
Hypofractionated radiation therapy showed no clear difference in late subcutaneous toxicity compared with conventionally fractionated radiation therapy (high certainty).
Hypofractionated radiation therapy showed no clear difference in breast cancer‐specific survival (BC‐SS) at 10 years compared with conventionally fractionated radiation therapy (high certainty).
Hypofractionated radiation therapy showed no clear difference in relapse‐free survival (RFS) at 10 years compared with conventionally fractionated radiation therapy (moderate certainty).
The review found no eligible studies for this question.
The intervention leads to lower overall survival (OS) (high certainty).
The intervention leads to lower disease free survival (DFS) (high certainty).
The intervention leads to higher congestive heart failure (CHF) (high certainty).
The intervention probably leads to higher left ventricular ejection fraction decline (LVEF) (moderate certainty).
The intervention may leads to higher brain metastasis as first site of relapse (low certainty).
Capecitabine‐containing regimens showed no clear difference in disease‐free survival (DFS)median compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).
Capecitabine‐containing regimens showed no clear difference in DFS: hormone receptor‐positivemedian compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).
Capecitabine‐containing regimens probably leads to lower DFS: hormone receptor‐negativemedian compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).